Literature DB >> 26191230

Bevacizumab induces A549 cell apoptosis through the mechanism of endoplasmic reticulum stress in vitro.

Li-Le Wang1, Rui-Cheng Hu1, Ai-Guo Dai1, Shuang-Xiang Tan1.   

Abstract

AIMS: To observe the effect of bevacizumab on human A549 cells and explore its mechanism.
METHODS: After different concentrations (0 μM, 1 μM, 5 μM, 25 μM) of bevacizumab treating in A549 cells, CCK8 assay detect the impact of bevacizumab on A549 cell proliferation and flow cytometry determine the effect of bevacizumab on human A549 cells apoptosis. Real-time PCR and Western blotting detect the changing expression of the target gene (CHOP, caspase-4, IRE1, XBP-1) on mRNA and Protein level.
RESULTS: Treatment with bevacizumab for 24-hr have induced cell death in a does-dependent manner dramatically (P<0.05). In terms of the mRNA level, expression of XBP-1 has increased obviously in each group (1 μM, 5 μM, 25 μM) (P<0.01); the expression of CHOP (25 μM) and caspase-4 (5 μM) have increased slightly (P<0.05). In terms of the protein level, the expression of CHOP has increased obviously in each group (1 μM, 5 μM, 25 μM) when compared with the control group (0 μM) (P<0.05). As for caspase-4 (5 μM, 25 μM), the expression have increased slightly when compared with the control group (0 μM) (P<0.05).
CONCLUSION: Bevacizumab can induce A549 cell apoptosis through the mechanism of endoplasmic reticulum stress.

Entities:  

Keywords:  A549 cell; Bevacizumab; apoptosis; endoplasmic reticulum stress

Mesh:

Substances:

Year:  2015        PMID: 26191230      PMCID: PMC4503101     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  15 in total

1.  The avastin story.

Authors:  Mikkael A Sekeres
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

2.  Changing end points in breast-cancer drug approval--the Avastin story.

Authors:  Ralph B D'Agostino
Journal:  N Engl J Med       Date:  2011-06-27       Impact factor: 91.245

3.  Asterosaponin 1 induces endoplasmic reticulum stress-associated apoptosis in A549 human lung cancer cells.

Authors:  Yachao Zhao; Changliang Zhu; Xiaofei Li; Zhipei Zhang; Yuan Yuan; Yunfeng Ni; Tonggang Liu; Sanming Deng; Jinbo Zhao; Yunjie Wang
Journal:  Oncol Rep       Date:  2011-06-23       Impact factor: 3.906

4.  Involvement of endoplasmic reticulum stress-mediated CHOP (GADD153) induction in the cytotoxicity of 2-aminophenoxazine-3-one in cancer cells.

Authors:  Shota Moriya; Keisuke Miyazawa; Tomohiro Kawaguchi; Xiao-Fang Che; Akio Tomoda
Journal:  Int J Oncol       Date:  2011-06-08       Impact factor: 5.650

5.  A synthetic compound, 1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one (B63), induces apoptosis and activates endoplasmic reticulum stress in non-small cell lung cancer cells.

Authors:  Jian Xiao; Yi Wang; Jing Peng; Lu Guo; Jie Hu; Menghua Cao; Xie Zhang; Hanqing Zhang; Zhouguang Wang; Xiaokun Li; Shulin Yang; Huiling Yang; Guang Liang
Journal:  Int J Cancer       Date:  2012-02-18       Impact factor: 7.396

6.  Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells.

Authors:  A Young Choi; Ji Hyun Choi; Hana Yoon; Keun-Young Hwang; Mi Hee Noh; Wonchae Choe; Kyung-Sik Yoon; Joohun Ha; Eui-Ju Yeo; Insug Kang
Journal:  Eur J Pharmacol       Date:  2011-07-08       Impact factor: 4.432

Review 7.  The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies.

Authors:  B Luo; A S Lee
Journal:  Oncogene       Date:  2012-04-16       Impact factor: 9.867

8.  Alkylphenols from the roots of Ardisia brevicaulis induce G1 arrest and apoptosis through endoplasmic reticulum stress pathway in human non-small-cell lung cancer cells.

Authors:  Guo-Yuan Zhu; Blenda Chi Kwan Wong; Aiping Lu; Zhao-Xiang Bian; Ge Zhang; Hu-Biao Chen; Yuen Fan Wong; Wang-Fun Fong; Zhijun Yang
Journal:  Chem Pharm Bull (Tokyo)       Date:  2012       Impact factor: 1.645

Review 9.  GRP78 induction in cancer: therapeutic and prognostic implications.

Authors:  Amy S Lee
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

10.  Vascular endothelial cell growth-activated XBP1 splicing in endothelial cells is crucial for angiogenesis.

Authors:  Lingfang Zeng; Qingzhong Xiao; Mei Chen; Andriana Margariti; Daniel Martin; Aleksandar Ivetic; Heping Xu; Justin Mason; Wen Wang; Gillian Cockerill; Kazutoshi Mori; Julie Yi-shuan Li; Shu Chien; Yanhua Hu; Qingbo Xu
Journal:  Circulation       Date:  2013-03-25       Impact factor: 29.690

View more
  5 in total

1.  [Association between endoplasmic reticulum stress pathway mediated by inositol-requiring kinase 1 and AECII apoptosis in preterm rats induced by hyperoxia].

Authors:  Hui-Min Ju; Hong-Yan Lu; Yan-Yu Zhang; Qiu-Xia Wang; Qiang Zhang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-09

2.  Fluorofenidone Inhibits the Proliferation of Lung Adenocarcinoma Cells.

Authors:  Zheng-Hao Deng; Jie Meng; Juan Tang; Gao-Yun Hu; Li-Jian Tao
Journal:  J Cancer       Date:  2017-07-04       Impact factor: 4.207

3.  Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer.

Authors:  Jie Xiao; Xiaobo Xu; Xiao Li; Yanli Li; Guobing Liu; Hui Tan; Hua Shen; Hongcheng Shi; Dengfeng Cheng
Journal:  Molecules       Date:  2016-09-30       Impact factor: 4.411

4.  Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.

Authors:  Alimu Adilijiang; Masaki Hirano; Yusuke Okuno; Kosuke Aoki; Fumiharu Ohka; Sachi Maeda; Kuniaki Tanahashi; Kazuya Motomura; Hiroyuki Shimizu; Junya Yamaguchi; Toshihiko Wakabayashi; Atsushi Natsume
Journal:  Molecules       Date:  2019-08-22       Impact factor: 4.411

5.  Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate.

Authors:  Kefeng Liu; Lin Dai; Chunxiao Li; Jing Liu; Luying Wang; Jiandu Lei
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.